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Chronic pain is a major health concern that aﬀects millions of people. There are no adequate long-term therapies for chronic pain
suﬀerers, leading to signiﬁcant cost for both society and the individual. The most commonly used therapy for chronic pain is the
application of opioid analgesics and nonsteroidal anti-inﬂammatory drugs, but these drugs can lead to addiction and may cause
side eﬀects. Further studies of the mechanisms of chronic pain have opened the way for development of new treatment strategies,
one of which is gene therapy. The key to gene therapy is selecting safe and highly eﬃcient gene delivery systems that can deliver
therapeutic genes to overexpress or suppress relevant targets in speciﬁc cell types. Here we review several promising viral vectors
that could be applied in gene transfer for the treatment of chronic pain and further discuss the possible mechanisms of genes of
interest that could be delivered with viral vectors for the treatment of chronic pain.
1.Introduction
Chronic pain is deﬁned by the U.S. Food and Drug
Administration as pain that persists for more than 3
months [1]. This leads to great suﬀering for patients and
results in a heavy burden for society. Chronic pain is not
simply related to anatomical reorganization; other changes
in neurotransmission and electrophysiological activity are
also involved in the pain pathway [2]. Conventional drug
treatment has many limitations, such as drug dependence,
tolerance, respiratory depression, and other systemic side
eﬀects. The development of gene therapy has opened the
possibility of using either nonviral or viral vectors to
transduce genes encoding antinociceptive substances to treat
chronic pain. Compared with nonviral systems, viral vectors
are much more eﬃcient in delivering exogenous genes to
target cells and inducing long-term gene expression [3].
However, not all viruses are suitable for gene delivery. For
instance, murine leukemia virus and lentivirus are both
retroviruses,butlentiviruscaninfectnondividingcells,while
murine leukemia virus cannot. This is the reason murine
leukemia virus is usually not used as a gene carrier in
neurological disease treatments [4]. It was reported that 2 of
11 children receiving gene therapy using a retroviral vector
caused leukemia. A possible reason is the integration of
viral gene may activate oncogenes. So the safety of retroviral
vectors has been paid more and more attention [5, 6]. The
ideal gene therapy vector should not be able to replicate its
own DNA and be conducive to long-term gene expression.
In addition, it should be nonpathogenic and nontoxic [7].
Viral vectors are generally created by deleting nonessential
genes from the virus while retaining the structural motifs
necessary to transfer its genome into the host [8]. Herpes
simplexvirus,adeno-associatedvirus,adenovirus,lentivirus,
and human foamy virus can all be used as viral vectors
for gene therapy for chronic pain. These viral vectors are
most commonly used because of their low immunogenicity,
natural integration ability and other features. What’s more,
they can infect both dividing and nondividing cells. In this
paper, published data about these vectors will be reviewed,
and their applications in gene therapy of chronic pain will be
discussed.
2. Herpes SimplexVirus(HSV)
Herpes simplex virus has neuronotropic features and natu-
rally maintains lifelong residency in the nucleus of infected2 Pain Research and Treatment
Table 1: Analgesic eﬀect of HSV vectors encoding therapeutic genes in pain treatment.
Pain models Gene product Inoculation References
Acute pain Preproenkephalin To the skin of dorsal hindpaw Wilson et al. [16]
Inﬂammatory pain Preproenkephalin A Infected on scariﬁed hind footpads Braz et al. [17]
Neuropathic pain Proenkephalin A Unilateral peripheral inoculation Meunier et al. [21]
Cutaneous hyperalgesia Preproenkephalin Subcutaneous inoculation Yeomans et al. [9]
Bladder hyperactivity and pain Preproenkephalin Injected into the bladder wall Yokoyama et al. [20]
Inﬂammatory pain Endomorphin-2 Subcutaneous inoculation Hao et al. [18]
Neuropathic pain Endomorphin-2 Subcutaneous inoculation Wolfe et al. [19]
Neuropathic pain IL-4 Subcutaneous inoculation Hao et al. [23]
Neuropathic pain sTNFRs Subcutaneous inoculation Peng et al. [24]
Neuropathic pain GAD67 Subcutaneous inoculation Hao et al. [25]
Neuropathic pain GAD67 Subcutaneous inoculation Liu et al. [26]
Inﬂammatory pain Nav1.7 antisense Subcutaneous inoculation Yeomans et al. [27]
Cancer pain Proenkephalin Subcutaneous inoculation Goss et al. [14]
neurons, making it suitable for transduction in the nervous
system [9]. Primary aﬀerent neurons are the natural targets
of HSV. HSV vector infects epithelial cells or neurons
directly after subcutaneous injection or topical application,
then penetrates peripheral aﬀerent nerve terminals, and
is retrogradely transported to cell bodies in dorsal root
sensory ganglia [10]. For the successful use of HSV vectors,
it is important to reduce their toxicity, modulate the time
course of transgene expression, and precisely target speciﬁc
cells [11]. A number of diﬀerent HSV-based nonreplicative
vectors with reduced cytotoxicity have been developed for
speciﬁc gene therapy applications [11, 12]. Recombinant
replication-defective HSV vectors expressing opioid peptides
or glutamic acid decarboxylase could inhibit nociceptive
neurotransmission at the ﬁrst synapse between primary
nociceptive and second-order neurons in the dorsal horn of
the spinal cord [1, 13] .T h e s ev i r a lv e c t o r sh a v eb e e ns h o w n
to have analgesic eﬀects in models of inﬂammatory pain,
neuropathic pain and cancer-related pain [1, 13, 14]. The
diﬀerent applications of HSV vectors for gene therapy of
chronic pain are summarized in Table 1.
Endogenous opiate peptides acting on synapses in the
dorsal horn of the spinal cord inhibit transmission of
nociceptive stimuli [15]. Wilson et al. ﬁrstly demonstrated
the antihyperalgesic potency of HSV-mediated preproenkep-
halin expression in DRG in a model of acute pain [16]. In
a model of ongoing polyarthritis-associated inﬂammatory
pain, Braz et al. enhanced enkephalin synthesis in sensory
neurons of polyarthritic rats and reduced hyperalgesia by
using recombinant HSV containing rat preproenkephalin A
cDNA [17]. It has been reported that application of HSV
vectors encoding preproenkephalin (PPE) or endomorphin-
2 (EM-2) can lead to an antiallodynic eﬀect in both rat and
monkey models of chronic pain [9, 18–20]. Administration
of the opioid receptor antagonists naloxone and naloxone
methiodide can block this analgesic eﬀect [21], suggesting
that endogenous opioid peptides reduce pain perception
through both central and peripheral opioid receptors. In
addition, animals did not develop tolerance to the continued
production of vector-mediated enkephalin over a period of
several weeks [22].
Hao et al. demonstrated that expression of interleukin-
4 (IL-4) in dorsal root ganglion (DRG) neurons achieved
via HSV-mediated gene transfer in vivo reduced mechanical
allodynia and thermal hyperalgesia in a spinal nerve ligation
(SNL) model of neuropathic pain. However, it did not
prevent the ultimate development of neuropathic pain [23].
Another cytokine, tumor necrosis factor-α (TNF-α), is over-
expressed by activated microglia and is correlated with the
emergence of mechanical allodynia [24]. Thus, HSV vector-
mediated gene transfer of the p55 TNF soluble receptor
(sTNFRs) could reduce pain, diminish the expression of
mTNF-α, and decrease the number of ED1-positive cells as
well as phosphorylation of p38 MAP kinase (p-p38) in the
dorsal horn. This suggests that sTNFR may block the TNF-α
signal after injury and reduce pain-related behavior [24].
Transfer of the gene that encodes glutamic acid decar-
boxylase (GAD67) into DRGs using a replication-defective
HSV vector could reduce neuropathic pain [25, 26]. This
may be because subcutaneous inoculation of HSV vec-
tor promotes the release of gamma aminobutyric acid
(GABA), which inhibits nociceptive neurotransmission [25,
26]. Increased expression of the Nav1.7 sodium channel in
sensory neurons occurs after peripheral inﬂammation and
potentially increases neuronal excitability. Application of a
recombinant HSV vector encoding an antisense sequence
to the Nav1.7 gene could produce a long-lasting or even
permanent decrease in inﬂammatory pain and hyperalgesia
in treated tissue without aﬀecting untreated tissue [27].
3.Adeno-AssociatedVirus(AAV)
Adeno-associated viral vectors are commonly used to deliver
therapeutic genes to target tissues because of their low
immunogenicity[28].AAV2isthemostwidelyusedserotypePain Research and Treatment 3
Table 2: Analgesic eﬀect of AAV vectors encoding therapeutic genes in chronic pain treatment.
Pain models Gene product Inoculation References
Neuropathic pain
Neuropathic pain
Neuropathic pain
Inﬂammation pain
Neuropathic pain
IL-10
shGCH1
Prepro-β-endorphin
μ-opioid receptor
BDNF
Intrathecal administration
Injected into sciatic nerve
Intrathecal administration
Injected into DRG
Injected into the dorsal horn
Milligan et al. [31]
Kim et al. [32]
Storek et al. [34]
Xu et al. [33]
Eaton et al. [35]
in gene therapy, while other new eﬃcient AAV vector types
such as AAV8 are under development. Recombinant AAV
can insert up to 6kb of foreign DNA into the host genome
[29]. AAV enters the cell through the internalization of
clathrin-coated pits and escapes endosomal degradation via
acidiﬁcation of the late endosome [30].
Spinal cord glia and glial proinﬂammatory cytokines
contribute to the initiation and maintenance of neuropathic
pain. This suggests that targeting glial activation or sup-
pressing proinﬂammatory cytokines may be an eﬀective
therapeutic strategy. Intrathecal administration of an AAV2
vector encoding an anti-inﬂammatory cytokine (IL-10) can
reverse neuropathic pain because IL-10 suppresses the pro-
duction of proinﬂammatory cytokines and also antagonizes
the signaling pathway activated by these cytokines [31].
Delivery of recombinant AAV encoding a small hairpin
RNA against GTP cyclohydrolase I (rAAV-shGCH1) into
DRG neurons can also relieve neuropathic pain through
downregulation of GTP cyclohydrolase I (GCH1) levels.
This may occur because GCH1 downregulation leads to
decreased microglial activation in the dorsal horn, implying
that transcriptional activation of GCH1 in the DRG is
associated with the development of pain and inﬂammation
[32].
Increased μ-opioid receptor expression in DRG neu-
rons achieved by recombinant AAV-mediated gene transfer
enhancedtheantinociceptiveeﬀectsofmorphineinrats.The
limitationofthisstudyisthatdirectinjectionofrecombinant
AAV into the DRG can lead to tissue damage [33]. Storek
et al. found that a self-complementary recombinant adeno-
associated virus serotype 8 (sc-rAAV8) expressing the anal-
gesic gene prepro-β-endorphin (ppβEP) led to signiﬁcant
reversal of mechanical allodynia, and this antiallodynic eﬀect
could be reversed by application of the μ-opioid antagonist
naloxone [34].
The levels of neurotrophins in the spinal cord have been
proposed to restore normal function after nervous system
injury. Intraspinal rAAV-mediated overexpression of brain-
derived neurotrophic factor (BDNF) reduces allodynia and
hyperalgesia induced by chronic constriction injury (CCI)
[35].However,directspinalapplicationofBDNFcontributes
to mechanical hypersensitivity and neuropathic pain via
activationofspinalmicroglia [36].Microglial-derived BDNF
then mediates central sensitization by attenuating inhibitory
synaptic transmission [37]. The exact eﬀect of BDNF in the
mechanism of pain still requires further clariﬁcation. Table 2
presents examples of AAV vector-mediated gene transfer in
pain models.
Eﬃcient and long-term gene transfer in the white matter
of the spinal cord, DRG neurons, and peripheral nerves can
be mediated by intraperitoneal or intramuscular injection of
AAV [38]. However, some important issues for gene therapy
stillneedtobeexplored.First,theextentoftransgeneexpres-
sion in the DRG following intrathecal injection is unknown.
Second, no studies have demonstrated the eﬀects of the
vector on the brain if the vector is injected at thoracic levels
of the spinal cord or higher. Third, the potential for infection
of other organs beyond the nervous system after intrathecal
injection of AAV requires further examination [39].
4. Adenovirus(AV)
Adenoviral vectors have a gene carrying capacity of 7.5kb
and can transduce both dividing and nondividing cells [4].
These viral vectors cannot integrate into the host genome,
so there is a low risk of insertional mutagenicity [40]. The
ﬁrst adenoviral vectors were constructed by substituting the
viral early gene 1 (E1) with a therapeutic gene. The E1 gene
is essential for adenoviral replication, so modiﬁcation of
the adenoviral genome through the deletion of E1 creates a
replication-defective vector and provides suﬃcient space for
foreign gene insertion [8]. More eﬃcient gene carriers were
obtained by altering more genes in the viral genome, such as
E2, or using polyethylene glycol (PEG) to facilitate transfer
[29, 41]. Adenoviruses have greater transgenic capacity if
more viral genes are removed [29, 41].
Loss of GABAergic inhibitory interneurons in the super-
ﬁcial dorsal horn of the spinal cord reduces GABAergic
tone and contributes to neuropathic pain after spinal cord
injury [42]. Vit et al. constructed a serotype 5 adenovector to
transfer the glutamic acid decarboxylase (GAD65) gene into
satellite glial cells (SGCs) of the trigeminal ganglion. They
found that GAD65 expression in the trigeminal ganglion led
to an analgesic eﬀect via increased GABA synthesis. This
analgesiceﬀectcouldbeblockedbyselectiveGABAA receptor
antagonists but not by an antagonist of GABAB receptors
[43]. In an inﬂammation model of persistent pain, admin-
istration of a recombinant adenovirus encoding endogenous
opioid β-endorphin into the cerebrospinal ﬂuid (CSF)
surrounding the spinal cord attenuated inﬂammatory hyper-
algesia but had no eﬀect on basal nociceptive responses [44].
Some anti-inﬂammatory cytokine genes can also be
transduced by adenoviral vectors to attenuate chronic pain.
Spinal cord glial cells are critical to the creation and
maintenanceofpainfacilitationthroughthereleaseofproin-
ﬂammatory cytokines. Adenoviral vectors encoding human4 Pain Research and Treatment
Table 3: Analgesic eﬀect of AV vectors encoding therapeutic genes in chronic pain treatment.
Pain models Gene product Inoculation References
Inﬂammatory pain
Pathological pain
Inﬂammatory pain
Neuropathic pain
GAD65
IL-10
β-endorphin
Interleukin-2
Injected into the left trigeminal ganglion
Intrathecal administration
Intrathecal administration
Intrathecal administration
V i te ta l .[ 43]
Milligan et al. [31]
Finegold et al. [44]
Yao et al. [46]
IL-10 (AD-h-IL10) blocked and reversed pain facilitation
[45]. Another cytokine gene, IL-2, can be delivered both by
adenoviralvectorsorplasmids,bothofwhichleadtoobvious
antinociceptive eﬀects [46, 47]. This eﬀect could be blocked
by naloxone, illustrating the relationship between IL-2 and
opioid receptors [47]. Previous studies have demonstrated
that IL-2 can suppress aﬀerent sensory transmission and
act as Ca2+ channel blockers, but the mechanism of IL-
2-induced antinociception is still unclear [46]. The eﬀects
of AV vector-mediated gene transfer in pain models are
summarized in Table 3.
5. Lentivirus(LV)
Lentiviralvectorshavetheadvantagesoflong-termtransgene
expression, low immunogenicity, and the ability to accom-
modate larger transgenes [48]. LVs belong to a subclass of
retroviruses that integrate into the host cell genome. Due to
their natural integration ability, LVs have a lot of potential
in central nervous system applications. LVs have been exten-
sivelyutilizedforexvivogenetransferbecauseoftheirstrong
tropism for neural stem and progenitor cells [29]. Single
microinjection of lentiviral vector-mediated intraspinal gene
transfer allowed for the diﬀusion of vectors along the
rostrocaudalaxis,thoughexpressionwasstillrestrictedtothe
gray matter of the ipsilateral dorsal spinal cord. In addition,
transgeneexpressioninglialcellsdidnotmodifyglialactivity
or alter animals’ locomotor behavior [49].
Lentiviral vectors are eﬃcient tools to induce sustained
expression of trophic factors in speciﬁc areas of the central
nervous system (CNS). Glial cell line-derived neurotrophic
factor (GDNF), which regulates neuronal survival and gene
expression, is expressed in both the central and peripheral
nervous systems. Reduction in GDNF and its receptor
levels in the nociceptive aﬀerent system may contribute
to the development and maintenance of neuropathic pain
states [50]. Intraspinal administration of lentiviral vectors
expressing GDNF lead to a large and sustained expression
of transgenes in both neurons and glial cells. Gene delivery
of GDNF via lentiviruses produced a partial but signiﬁcant
reversal of thermal and mechanical hyperalgesia [51].
Nuclear factor κB(NF -κB)isapleiotropicfactorinvolved
in transcriptional control of some inﬂammation and pain-
related molecules. In a model of chronic constriction injury
(CCI), lentiviral vector-mediated overproduction of IκBα,
which is a natural endogenous inhibitor of NF-κB, inhibited
NF-κB activity in glial cells of the dorsal spinal cord
and produced prolonged antihyperalgesic and antiallodynic
eﬀects. IκBα overproduction also reduced expression of
interleukin-6 (IL-6) and inducible nitric oxide synthase
(iNOS), suggesting that IκBα may relieve pain via the
prevention of CCI-associated expression of IL-6 and iNOS
[52].
6.HumanFoamyVirus(HFV)
Human foamy virus, the ﬁrst identiﬁed human retrovirus,
is nonpathogenic and has several unique features related
to gene transfer, making it a promising vector system for
gene therapy [53]. The potential advantages of FV vectors
include a broad host range, the largest packaging capacity
of any retrovirus and the ability to persist in quiescent cells
[54, 55]. Because of these features, foamy vectors have the
unique potential to safely and eﬃciently deliver several genes
into a number of diﬀerent cell types in vivo [54]a n da r e
especially useful for transducing hematopoietic cells. They
have been demonstrated to mediate eﬃcient and stable gene
transfer into hematopoietic stem cells (HSCs) in mouse
and canine animal models, which indicates that they have
a unique integration proﬁle and suggests they may be safer
than gammaretroviruses or lentiviral vectors [55].
Liu et al. found that gene transfer using a human foamy
virus(HFV)vectorcanreducebelow-injurylevelmechanical
allodynia and thermal hyperalgesia after spinal cord injury
(SCI). In that study, the glutamic acid decarboxylase (GAD)
gene was transferred into dorsal root ganglion (DRG) cells
using a novel HFV vector that expresses GAD (vector
rdvGAD67) for 7 days after T13 spinal cord hemisection
to achieve release of gamma-aminobutyric acid (GABA).
Subcutaneous inoculation of a replication-defective HFV
vector attenuated pain evoked by SCI and also enhanced the
productionofGADandtonicGABAreleasefromtransduced
DRG neurons [56].
7.Possible Mechanismsof
ViralVector-MediatedGeneTherapyfor
ChronicPain
Studies have showed that viral vector-mediated therapeutic
genes play signiﬁcant analgesic eﬀects in several diﬀerent
pain models. Understanding the mechanism of viral vector
function in the gene therapy of chronic pain will help us to
improve treatment eﬃcacy and search for new therapeutic
strategies. The mechanisms of viral vector-based gene ther-
apy involve several pathways (Figure 1).Somegeneproducts,
such as GABA, can block nociceptive neurotransmission at
the ﬁrst synapse between the primary peripheral nociceptor
and the second order neuron in the spinal cord. Anti-
inﬂammatory cytokines expressed by viral vector-mediatedPain Research and Treatment 5
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Figure 1: Possible mechanisms of viral vector actions in gene therapy of chronic pain. Recombinant viral vectors encoding therapeutic genes
infect target cells and express antinociceptive substances after subcutaneous inoculation or intrathecal administration. Gene products such
as GAD and BDNF can lead to the release of GABA, which is an inhibitory neurotransmitter. IL-4 and IL-10 can suppress the expression of
proinﬂammatory cytokines produced by activated glial cells and antagonize the signaling pathway activated by these cytokines. Endogenous
opioid peptides have analgesic eﬀects through opioid receptors. Nav1.7 antisense can prevent an increase in Nav1.7 expression and decrease
inﬂammatory hyperalgesia.
therapeutic gene can reduce central neuroimmune activa-
tion. Antisense or RNA sequences enact their analgesic eﬀect
by reducing the expression of gene products essential to the
development of chronic pain [2].
Activation of nociceptive primary neurons leads to
central release of excitatory neurotransmitters or neu-
romediators, such as glutamate, substance P, and ATP,
which are all related to pathological pain [43]. Inhibitory
interneuronsanddescendingmodulatorycontrolsystemsare
dysfunctional after nerve injury, leading to disinhibition or
facilitation of spinal cord dorsal horn neurons and to further
central sensitization [57]. Spinal cord glial cells are activated
via neuronal chemokines, neurotransmitters, and substances
released by damaged neurons [58]. Activated glial cells
further enhance neuronal excitability by releasing cytokines,
especially proinﬂammatory cytokines, thus increasing the
concentration of glutamate and the downregulation of
GABA receptor function [57, 58].
Proinﬂammatory cytokines (TNF-α,I L - 1 β,I L - 6 ,e t c . )
enhance pain expression by increasing the excitability of dor-
sal horn pain transmission neurons and upregulating AMPA
and NMDA receptors [45]. Anti-inﬂammatory cytokines
(IL-4, IL-10) are known to suppress the production of proin-
ﬂammatory cytokines that are released by activated spinal
cord glial cells. It has been shown that viral vectors encoding
anti-inﬂammatory cytokines can block and reverse pain
facilitation in various pain models. Hao et al. demonstrated
that HSV-mediated expression of IL-4 reduced c-Fos expres-
sion in the dorsal horn in the SNL model of neuropathic
pain, decreased levels of IL-1β and PGE2 in the dorsal horn
and reduced the phosphorylation of spinal p-p38 [23].
Endomorphin-2, β-endorphin, and proenkephalin,
which are all endogenous opioid peptides, are often encoded
in viral vectors because of their analgesic eﬀect. Endogenous
opioid peptides evoke the analgesic eﬀect by stimulating
opioid receptors. These receptors can be found in the
central and peripheral terminals of primary nociceptors,
second-order neurons in dorsal horn of spinal cord and
other tissues such as brain [59]. Transduction of other
genes, such as GAD and BDNF, via viral vector-mediated
gene transfer can increase the release of GABA to relieve
pain [46, 51]. Naik et al. speculated that GABA-mediated
depolarization inﬂuences the excitability of sensory neurons
both in cell bodies and nerve terminals by inactivating6 Pain Research and Treatment
other voltage-sensitive channels, such as Ca2+ and Na+.I ti s
also possible that the GABA-activated Cl− current directly
inhibits ATP-evoked excitatory currents in DRG neurons
[60].
8. Prospects
Viralvector-mediatedgenetransferhasbeenappliedinsome
clinical trials to evaluate its safety and tolerance. In 2002, a
phase I study of replication-competent adenovirus-mediated
double suicide gene therapy of prostate cancer demonstrated
that this treatment could be safely applied to humans [61].
Other clinical trials of viral vectors for gene therapy have also
been shown to be safe and well tolerated, but the eﬀect of
this treatment was not very signiﬁcant [62, 63]. For chronic
pain, the ﬁrst human trial of gene therapy began enrolling
subjects in December 2008. This was a phase 1 study of a
nonreplicating herpes simplex virus- (HSV-) based vector
that expressed preproenkephalin in patients with intractable
pain from cancer [64]. These clinical trials promote the
development of gene therapy for chronic pain.
Viral vectors for gene therapy are currently mainly in
preclinical trials. Although gene therapy is a promising new
treatment and has some advantages over other therapies,
there are still several problems left to be solved. Transfection
eﬃciency, speciﬁc targeting, and the safety of viral vectors
need to be improved. Potential mutations, antiviral response
and total ineﬃcacy also limit the application of gene therapy.
Achieving a restricted, local production of therapeutic trans-
genes may decrease some adverse reactions. Previous studies
focused on the application of single therapeutic gene, while
codelivering antagonizing genes may decrease the side eﬀects
and improve eﬃcacy. For instance, Xu et al. demonstrated
that recombinant AAV-mediated transgene expression of
μ-opioid receptor which targets speciﬁcally DRG neurons
could avoide undesired systemic eﬀects of opioids and also
enhance the antinociceptive eﬀects of morphine [33]. The
development of biomedical technologies will lead to the
construction of safer and more eﬃcient viral vectors. It is
believed that successful application of viral vectors for gene
therapy could lead to a breakthrough in the treatment of
chronic pain and other diseases.
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